Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides

Journal of Medical Virology

Volumn 70, Issue 1, 2003, Pages 86-90

  Temperton, Nigel J ^a   Quenelle, Debra C ^b   Lawson, Keirissa M ^a   Zuckerman, Jane N ^a   Kern, Earl R ^b   Griffiths, Paul D ^a   Emery, Vincent C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adjuvant; CpG ODN; Cytomegalovirus; DNA vaccine

Indexed keywords

ADJU PHOS; ALUMINUM PHOSPHATE; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CPG ISLAND; CYTOMEGALOVIRUS INFECTION; EMULSION; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PLASMID; VACCINATION; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIBODY FORMATION; CYTOMEGALOVIRUS; HUMANS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHATES; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; PHOS;

EID: 0345700245     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10357     Document Type: Article

References (42)

1. Berencsi K, Rando RF, deTaisne C, Paoletti E, Plotkin SA, Gonczol E. 1993. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. J Gen Virol 74(Pt 11):2507-2512.
2. Berencsi K, Gyulai Z, Gonczol E, Pincus S, Cox WI, Michelson S, Kari L, Meric C, Cadoz M, Zahradnik J, Starr S, Plotkin S. 2001. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183:1171-1179.
3. Britt WJ, Vugler L, Butfiloski EJ, Stephens EB. 1990. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64:1079-1085.
4. Chee MS, Bankier AT, Beck S, Bohni R, Brown CM, Cerny R, Horsnell T, Hutchison CA III, Kouzarides T, Martignetti JA. 1990. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol 154:125-169.
5. Davis HL, McCluskie MJ. 1999. DNA vaccines for viral diseases. Microbes Infect 1:7-21.
6. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751-1767.
7. Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin SA, Gonczol E. 1999. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17:50-58.
8. Endresz V, Burian K, Berencsi K, Gyulai Z, Kari L, Horton H, Virok D, Meric C, Plotkin SA, Gonczol E. 2001. Optimization of DNA immunization against human cytomegalovirus. Vaccine 19:3972-3980.
9. Frey SE, Harrison C, Pass RF, Yang E, Boken D, Sekulovich RE, Percell S, Izu AE, Hirabayashi S, Burke RL, Duliege AM. 1999. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 180:1700-1703.
10. Gonczol E, Plotkin S. 2001. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 1:401-412.
11. Gonzalez Armas JC, Morello CS, Cranmer LD, Spector DH. 1996. DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921-7928.
12. Griffiths PD, Baboonian C. 1984. A prospective study of primary cytomegalovirus infection during pregnancy: final report. Br J Obstet Gynaecol 91:307-315.
13. Griffiths PD, McLean A, Emery VC. 2001. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 19:1356-1362.
14. Gurunathan S, Klinman DM, Seder RA. 2000. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927-974.
15. Hwang ES, Kwon KB, Park JW, Kim DJ, Park CG, Cha CY. 1999. Induction of neutralizing antibody against human cytomegalovirus (HCMV) with DNA-mediated immunization of HCMV glycoprotein B in mice. Microbiol Immunol 43:307-310.
16. Klinman DM, Yamshchikov G, Ishigatsubo Y. 1997. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158:3635-3639.
17. Klinman DM, Barnhart KM, Conover J. 1999. CpG motifs as immune adjuvants. Vaccine 17:19-25.
18. Klinman DM, Ishii KJ, Verthelyi D. 2000. CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr Top Microbiol Immunol 247:131-142.
19. Krieg AM. 2000. The role of CpG motifs in innate immunity. Curr Opin Immunol 12:35-43.
20. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-549.
21. Mach M, Kropff B, Dal Monte P, Britt W. 2000. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J Virol 74:11881-11892.
22. + virus-specific cytotoxic T lymphocytes. J Med Virol 43:103-110.
23. Morello CS, Cranmer LD, Spector DH. 2000. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 74:3696-3708.
24. Pande H, Campo K, Tanamachi B, Forman SJ, Zaia JA. 1995. Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand J Infect Dis 99(suppl):117-120.
25. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, Britt W, Burke RL. 1999. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180:970-975.
26. Plotkin SA. 1999. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 18:313-325.
27. Plotkin SA. 2001. Vaccination against cytomegalovirus. Arch Virol Suppl 17:121-134.
28. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. 2001. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 11:191-200.
29. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795-2804.
30. Robinson HL, Pertmer TM. 2000. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 55:1-74.
31. Schleiss MR, Bourne N, Jensen NJ, Bravo F, Bernstein DI. 2000. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83. Viral Immunol 13:155-167.
32. Spaete RR, Perot K, Scott PI, Nelson JA, Stinski MF, Pachl C. 1993. Coexpression of truncated human cytomegalovirus gH with the UL115 gene product or the truncated human fibroblast growth factor receptor results in transport of gH to the cell surface. Virology 193:853-861.
33. Stagno S. 1990. Cytomegalovirus. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. Philadelphia: WB Saunders. p 240-281.
34. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA. 1986. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256:1904-1908.
35. Stratton KR, Durch JS, Lawrence RS, editors. 2001. Vaccines for the 21st century: a tool for decisionmaking. Washington DC: National Academy Press.
36. Temperton NJ. 2002. DNA vaccines against cytomegalovirus: current progress. Int J Antimicrobial Agents 19:169-172.
37. Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, Caulfield MJ, Bohannon KE, Volkin DB, Evans RK. 1999. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 18:18-28.
38. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M. 1996. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77:1537-1547.
39. Utz U, Britt W, Vugler L, Mach M. 1989. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 63:1995-2001.
40. Weeratna R, Brazolot Millan CL, Krieg AM, Davis HL. 1998. Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 8:351-356.
41. Wells DE, Vugler LG, Britt WJ. 1990. Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells. J Gen Virol 71(Pt 4):873-880.
42. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579.